All In Biotech

Drug Trial Radar · NCT06445075

Efficacy and Safety of Apitegromab for the Treatment of Adults Who Are Overweight or Obese

A Phase 2 Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Apitegromab in Overweight and Obese Adult Subjects

Last checked: Nov 20, 2026Latest source record: Jan 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 102 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

102

Actual

Start

May 21, 2024

Primary completion

Mar 4, 2025

Study completion Jun 17, 2025

Sponsor

Lead sponsor
Scholar Rock, Inc.Industry
Sponsor type
Industry
First posted
Jun 6, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

A phase 2 study to evaluate the effects of apitegromab as an adjunctive therapy to GLP-1 receptor agonist therapy in subjects with overweight or obesity

Conditions

  • Overweight and Obesity

Interventions

  • ApitegromabDrug

    Apitegromab (SRK-015) is a fully human anti-proMyostatin monoclonal antibody (mAb) that specifically binds to human pro/latent myostatin, inhibiting myostatin activation. Apitegromab was administered every 4 weeks by intravenous (IV) infusion.

  • PlaceboDrug

    Same appearance and composition as apitegromab drug product but does not contain the active ingredient. Placebo was administered every 4 weeks by intravenous (IV) infusion.

  • TirzepatideDrug

    Glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist. Tirzepatide was administered every week by subcutaneous injection.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from Baseline in total Lean Body Mass (kg) at 24 weeksTime frame: Baseline and 24 weeks

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • ProSciento CRU

    Chula Vista, California

  • AdventHealth Translational Research Institute

    Orlando, Florida

  • Great Lakes Clinical Trials, LLC d/b/a Flourish Research

    Chicago, Illinois

  • Tandem Clinical Research GI, LLC

    Marrero, Louisiana

  • Alliance for Multispecialty Research, LLC

    Norman, Oklahoma

  • Apex Mobile Clinical Research

    Bellaire, Texas

  • Clinical Trials of Texas, LLC dba Flourish Research

    San Antonio, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.